NovoCure (NVCR) AI Stock Analysis

• Market Cap: $1.54B
• Dividend Yield: N/A
• Average Volume (3M): 2.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: 11.17%
• EPS Growth: -15.64%
• Country: US
• Employees: 1,488
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.22
• Shares Outstanding: 113,794,395
• 10 Day Avg. Volume: 2,681,346
• 30 Day Avg. Volume: 2,459,189
• PEG Ratio: 0.49
• Price to Book (P/B): 4.23
• Price to Sales (P/S): 2.20
• P/FCF Ratio: -19.05
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 2.59
• Enterprise Value/Gross Profit: 3.48
• Enterprise Value/Ebitda: -12.97
• 1Y Price Target: $25.50
• Price Target Upside: 88.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -1.6
• Revenue Forecast (FY): $681.49M

• Rating: 52 Neutral
• Price Target: $14.00 ▲(3.55% Upside)
• Action: Reiterated Date: 03/02/26
• Date: Action: Reiterated 03/02/26

The score is held back primarily by weak financial performance, driven by persistent losses and negative free cash flow. Offsetting this, the latest earnings call included constructive guidance toward adjusted EBITDA breakeven and highlighted meaningful pipeline and regulatory progress, while technical signals are moderately supportive. Valuation remains constrained by negative earnings and no dividend.

Positive Factors

Clinically validated, proprietary TTFields therapy and new FDA approval

Regulatory approval and Phase 3 positive results create durable clinical validation for TTFields in pancreatic cancer. That expands the addressable market beyond GBM, strengthens the technology moat, and improves the company's leverage in payer and provider discussions over the next several years.

Record revenue with high gross margins and recurring consumable demand

Revenue re‑acceleration combined with mid‑70s gross margins indicates a scalable model driven by recurring sales of consumable arrays. High gross margins provide structural leverage to improve operating profitability as patient volumes and non‑GBM adoption grow, supporting a durable path to breakeven.

Stronger liquidity and lower leverage after major debt repayment

Meaningful debt reduction and a $448M cash position materially reduce refinancing risk and give management runway to fund launches, trials and commercialization investments. Improved capital structure increases flexibility to achieve adjusted EBITDA breakeven without immediate reliance on equity raises.

Negative Factors

Persistent negative cash flow and net losses

Sustained operating and free cash outflows reflect ongoing cash burn despite revenue growth. Without durable conversion to positive EBITDA or material margin improvement, the company will remain reliant on balance sheet resources or financing, increasing dilution or financial risk over the medium term.

Payer coverage and reimbursement lag for new indications

A 1–2 year reimbursement timeline for Optune Pax materially delays revenue realization from a major new indication. Persistent coverage lag creates structural headwinds to scaling non‑GBM revenue, limits near‑term margin benefits, and raises execution risk in payer negotiations and formulary access.

High R&D spend and slower-than-expected product launches

Elevated R&D to fund late‑stage trials and the slow Optune Lua rollout increases fixed costs and delays diversification of revenue streams. If new product adoption remains sluggish, high development spending will extend the timeline to sustainable profitability and strain returns on investment.

NovoCure Business Overview & Revenue Model

Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

How the Company Makes Money

NovoCure generates revenue primarily through the sale of its Optune devices and related consumables, such as the TTFields transducer arrays, which are used in conjunction with the therapy. The company also earns revenue from insurance reimbursements, as many health insurance plans cover the cost of Optune therapy for eligible patients. Significant partnerships with healthcare providers and collaborations with research institutions enhance its market reach and credibility. Additionally, NovoCure may benefit from expanding its indications for TTFields therapy beyond glioblastoma and mesothelioma, creating new revenue opportunities.

NovoCure Financial Statement Overview

Summary

Revenue re-accelerated in 2025 and gross margin remains strong (~75%), and leverage improved (debt-to-equity down to ~0.85). However, operating results are still meaningfully negative (net margin ~-21%) and cash burn is significant with negative operating cash flow (~-$49M) and free cash flow (~-$76M) in 2025, which remains the primary financial risk.

Income Statement

Revenue has re-accelerated in 2025 (up ~8% vs. 2024 after a decline in 2023), and gross margins remain strong (~75% in 2025). However, profitability is still materially negative: 2025 net margin is about -21% and operating profitability remains weak, reflecting ongoing cost pressure relative to the current revenue base. Overall, the top line is improving, but the company has not yet translated it into sustainable earnings.

Balance Sheet

Leverage has improved meaningfully, with debt-to-equity falling to ~0.85 in 2025 from ~1.90 in 2024, indicating a healthier capital structure vs. last year. Equity remains positive, which supports financial flexibility. The key weakness is continued losses driving negative returns on equity (about -40% in 2025), which can erode balance-sheet strength over time if not corrected.

Cash Flow

Cash generation is currently a concern: operating cash flow and free cash flow are negative in both 2024 and 2025 (2025 operating cash flow about -$49M; free cash flow about -$76M). While free cash flow burn was slightly worse in 2025 versus 2024, the broader trend versus earlier years shows a shift from positive cash generation (2020–2022) to sustained cash outflows, increasing reliance on balance-sheet resources or external funding until profitability improves.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	655.35M	605.22M	509.34M	537.84M	535.03M
Gross Profit	488.47M	468.04M	381.06M	422.97M	420.15M
EBITDA	-119.05M	-109.58M	-177.45M	-67.89M	-38.38M
Net Income	-136.23M	-168.63M	-207.04M	-92.53M	-58.35M
Balance Sheet
Total Assets	804.33M	1.24B	1.15B	1.19B	1.14B
Cash, Cash Equivalents and Short-Term Investments	457.52M	959.87M	910.62M	969.42M	938.51M
Total Debt	290.00M	683.35M	596.24M	584.27M	581.90M
Total Liabilities	463.86M	880.61M	783.63M	750.48M	729.00M
Stockholders Equity	340.47M	360.18M	362.50M	441.17M	410.49M
Cash Flow
Free Cash Flow	-75.68M	-69.22M	-100.43M	9.43M	58.59M
Operating Cash Flow	-49.03M	-26.37M	-73.34M	30.79M	82.76M
Investing Cash Flow	437.28M	-140.24M	184.15M	-139.96M	-144.83M
Financing Cash Flow	-451.34M	90.31M	15.79M	15.49M	25.70M

NovoCure Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCR, the sentiment is Positive. The current price of 13.52 is above the 20-day moving average (MA) of 11.71, above the 50-day MA of 12.74, and below the 200-day MA of 13.74, indicating a neutral trend. The MACD of 0.25 indicates Negative momentum. The RSI at 57.31 is Neutral, neither overbought nor oversold. The STOCH value of 61.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVCR.

NovoCure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMO	72 Outperform	$78.48B	24.61	14.30%	2.45%	-6.18%	-14.06%
BLFS	62 Neutral	$1.09B	-71.97	-5.20%	―	-18.82%	92.56%
ATRC	60 Neutral	$1.54B	-128.34	-2.40%	―	15.80%	26.94%
NVCR	52 Neutral	$1.54B	-11.06	-38.89%	―	11.17%	-15.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QDEL	45 Neutral	$1.54B	-1.36	-46.15%	―	-3.43%	38.98%
SMTI	42 Neutral	$183.00M	-4.72	-27.19%	―	30.55%	-340.19%

NovoCure Corporate Events

NovoCure Has Medicare Billing Privileges Reinstated by CMS

On February 2, 2026, Novocure Inc. disclosed that the Centers for Medicare & Medicaid Services had revoked its Medicare billing privileges retroactive to December 17, 2025, due to an administrative issue in its triannual re-validation rather than a substantive compliance failure. On February 24, 2026, CMS rescinded the revocation and reinstated Novocure’s billing privileges retroactively, and the company, which continued serving existing and new patients during the ineligible period, expects no ultimate impact on its ability to recognize revenue from those services.

The brief interruption in billing status highlights operational reliance on accurate administrative processes in U.S. government reimbursement systems but appears unlikely to affect Novocure’s financial reporting for the affected period. Stakeholders may view the quick reversal and retroactive reinstatement as limiting potential disruption to cash flows and signaling that the issue was procedural rather than a reflection of underlying regulatory risk.

The most recent analyst rating on (NVCR) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.

Novocure Wins FDA Approval for Optune Pax in Pancreatic Cancer

On February 11, 2026, Novocure announced that the U.S. Food and Drug Administration approved its Optune Pax device for use with gemcitabine and nab-paclitaxel in adult patients with locally advanced pancreatic cancer, marking the first new FDA-approved treatment for this indication in nearly 30 years. The wearable device, which delivers Tumor Treating Fields non-invasively, demonstrated statistically significant improvements in overall survival, pain progression, one-year survival rates and quality-of-life measures in the Phase 3 PANOVA-3 trial, without adding systemic toxicity, potentially reshaping the treatment landscape for this highly lethal cancer and expanding Novocure’s role in pancreatic oncology.

The most recent analyst rating on (NVCR) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.

NovoCure Faces CMS Billing Revocation, Revenue Impact Uncertain

On January 30, 2026, Novocure Inc. disclosed that CMS had revoked its billing privileges for the company’s products, retroactive to December 17, 2025, due to an administrative issue with its triannual re-validation rather than any substantive failure to qualify. While Novocure has submitted a Corrective Action Plan and continues to treat existing and new patients, it cannot bill Medicare, Medicare Advantage and other CMS-related payors during the revocation period and estimates that it will be unable to recognize roughly $13 million in monthly revenue from these payors until billing privileges are restored, with the timing, ultimate resolution and extent of recoverable revenue for services rendered in the interim remaining uncertain.

The most recent analyst rating on (NVCR) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.